Background and Aims: EGFRvIII is the most prevalent glioblastoma mutation, occurring in more than 25% of glioblastomas. EGFRvIII cells release microvesicles that contain proteins, miRNAs, and mRNAs that enhance the growth and survival of surrounding tumor cells. However, little is known about the maturation process and regulatory mechanisms of secreted vesicles in EGFRvIII cells. Methods: Signal peptide peptidase (SPP) provides a fascinating mechanism for protein cleavage and subsequent dislocation in the endoplasmic reticulum transmembrane domain. Results: In this study, we reported that SPP facilitates the secretion of cytokines in vitro and promotes tumor progression in mice. Human cytokine antibody arrays revealed that EGFRvIII secreted higher levels of cytokines, but these levels were significantly reduced following SPP knockdown, suggesting that cytokines in EGFRvIII secretion profiles play important roles in GBM development. Identical results were confirmed in intracellular maturation tracking of TGF-b1 in mouse serum. Clinically, analyses of GBM patient data from the database revealed that HM13 expression was closely related to patient prognosis and survival, suggesting an influence by the secreted vesicles of EGFRvIII tumor cells. Conclusions: Collectively, our study identifies that SPP affects EGFRvIII secretion profiles and thus promotes tumor progression, providing further understanding of the formation of secreted vesicles and driving role of EGFRvIII in GBM.
Introduction
Gene amplification and DNA rearrangement are frequently observed in GBM [1] . In particular, nearly 60% of GBMs are accompanied by epidermal growth factor receptor (EGFR) amplification [2, 3] , and approximately one-third of GBM contains the EGFRvIII mutation, which is the most common EGFR mutation in GBM [4] . Due to the genomic deletion of exons 2-7 [3] , EGFRvIII has a greatly truncated extracellular domain [5] and therefore is constitutively activated, promoting tumor progression by inducing oncogenic transformation of adjacent cells through paracrine paths [6] as well as through the secretion of microvesicles derived from EGFRvIII tumor cells [7] . However, the molecular mechanisms of secreted vesicles in EGFRvIII cells have largely remained a mystery, and it is therefore important to elucidate how secreted vesicles in EGFRvIII cells are regulated, with the goal of finding new points of intervention.
The signal peptide peptidase (SPP), encoded by HM13, is a member of the intramembrane cleaving proteases involved in leader peptide remnant release from the endoplasmic reticulum membrane [8] . There is increasing evidence that SPP plays important roles in cell signaling [9] , surveillance [10] , regulation [11] , cell intracellular communication [12] , and cancer [13, 14] . Here, we show that SPP contributes to GBM progression by affecting EGFRvIII secretion profiles. Experimentally, in mouse blood, there was significantly decreased expression of TGF-b1 in SPP knockdown groups. Coupled with the results of cytokine assays and TGF-b1 tracing in vitro, this study shows that the signal peptide peptidase may be a critical trigger point in regulating EGFRVIII secretion profiles for GBM.
Materials and Methods

Human Specimens and Cell Culture
Human tumor samples were obtained from patients undergoing surgical resection at TianTan Hospital (Beijing, China). All patients provided written informed consent, and all human experiments were approved by the Ethics Committee of TianTan Hospital. Human GBM cancer cell lines (U87, LN229, and U251) were purchased from the American Type Culture Collection. U87-EGFRvIII (a GBM cell line carrying mutant EGFR) was a kind gift from Harbin Medical University (Professor. Ren Huan). U87-EGFRvIII cells were maintained with G418 (Sigma, St. Louis, MO, USA) at a concentration of 400 mg/mL. All cells were incubated at 37°C with 5% CO2.
Cytokine Array
The profiles of cytokines secreted by GBM cancer cells were detected in the culture supernatants using a Human Cytokine Array (RayBiotech, Guangzhou, China) according to the manufacturer's instructions. The cytokines with distinct differences in expression were screened out.
In Vitro Assays
For siRNA transfection, GBM cancer cells were plated at 2 9 10 5 cells/mL in serum-free media and transfected with siRNA duplexes using Lipofectamine 3000 Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. The siRNA sequences: 5 0 -TGCCTGAAACAATCACCAGC-3 0 (siRNA-1),
For lentivirus preparation and in vitro infection, lentiviral vectors expressing nonsense control (Lenti-NC) and Lenti-siHM13 (5 0 -TGCCTGAAACAATCACCAGC-3 0 ) were all generated by GenePharma (Shanghai, China). Cell infections were carried out according to GenePharma's recommendations. For real-time PCR assay, real-time PCR (RT-PCR) was performed according to the manufacturers' instructions as previously described [15] .
For ELISA, TGF-b1 and TGF-a ELISA kits were purchased from R&D Systems and used according to the manufacturer's instructions, and the samples were subsequently analyzed by a Microplate Reader at 450 nm.
In Vivo Assays
For the orthotopic nude mouse model, 4-week-old BALB/c-A nude mice were purchased from Chinese Academy of Medical Science (Beijing, China) Animal Center and housed in pathogenfree conditions. The intracranial tumor models were established as previously described [16] . Briefly, 5 9 10 5 GBM cells infected with Lenti-siHM13 were stereotactically injected into mouse brains using cranial guide screws. After survival observation, mice were sacrificed, and the brains were extracted for hematoxylineosin (H&E) and immunohistochemical (IHC) staining. For immunohistochemical assays, tumor samples embedded in paraffin were sectioned at a thickness of 3 lm. Antigen retrieval was conducted using a pressure cooker for 25 min in 0.01 M citrate buffer. Tissue slices were incubated with antibodies overnight at 4°C. Cells were incubated with DAB for immunostaining for approximately 1 min according to the manufacturer's 
Immunofluorescence and Microscopy
Immunofluorescence staining was performed using primary antibodies against smad2, p-smad2, smad3, and p-smad3 (1:100 dilutions, Cell Signaling Technology, Danvers, MA, USA), followed by 1 h of incubation with Alexa Fluor 488 donkey antimouse IgG (H+L) and Alexa Fluor 594 goat anti-rabbit IgG (H+L) (Molecular Probes, Life Technology, Eugene, OR, USA) at room temperature. All fluorescent fields were visualized using an FV-1200 laser scanning confocal microscope.
Data Analysis
All experimental data are expressed as the mean AE SD. The t-test was used for comparison between two groups, and one-way ANOVA was used to determine significance among multiple groups. Statistical significance was determined at *P < 0.05, **P < 0.01 or ***P < 0.001.
Results
HM13 is Upregulated in High-Grade Gliomas
We analyzed glioma samples from patients with different grades in the CGGA cohort. Among the 301 samples, 173 were diagnosed as low-grade gliomas (WHO grade II and grade III), and 128 were diagnosed as high-grade gliomas (WHO grade IV). The expression levels of HM13 are increased in high-grade gliomas (HGG) compared to low-grade gliomas (LGG). To avoid deviation resulting from monocentric data, we also analyzed different grades samples from TCGA, REMBRANDT, and GSE16011 (Table 1) . We confirmed that HM13 was significantly overexpressed in HGG samples compared to LGG samples ( Figure 1A ). To determine whether HM13 expression levels determine the clinical progression or outcome of glioma patients, we examined the overall survival rates of the glioma patients (samples from CGGA, REMBRANDT, and GSE16011) using Kaplan-Maier analysis and log-rank comparison. The results showed that high HM13 expression was associated with a decreased survival period in patients ( Figure 1B) . Furthermore, we analyzed the HM13 expression in EGFRvIII and non-EGFRvIII patients in the CGGA database. The results showed that HM13 was overexpressed in EGFRvIII samples compared to non-EGFRvIII samples ( Figure 1C ).
HM13 Expression is Associated with Tumor Grade in Human Glioma Specimens
Our results showed that HM13 was closely related to tumor grade and patient survival in glioma patients. To further explore the role of the HM13 gene in gliomas, we first measured the expression of HM13 protein in 63 glioma specimens of different grades. Western blot and immunohistochemistry results showed that the protein expression of HM13 was dramatically upregulated with increased grade (Figure 2A,B) . Additionally, the mRNA expression of HM13 was assayed by qPCR. According to the results of the experiment, the expression of HM13 mRNA was increased in HGG specimens compared to lower-grade gliomas, but this difference was not statistically significant between grade II and grade III ( Figure 2C ).
Signal Peptide Peptidase (HM 13) Knockdown Abrogates the Cytokines Production from EGFRvIII Cancer Cells
To identify the cytokines secreted by EGFRvIII cancer cells that enhance tumorigenic ability, the cytokine profiles of cell supernatants from U87, U87EGFRvIII, and U87EGFRvIII infected with Lenti-siHM13 were analyzed using a Human Cytokine Antibody Array from RayBiotech. We first selected the most effective small interfering RNA for knocking down HM13 using the transfection reagent Lipofectamine 3000 ( Figure 3A ). The expression of four cytokines (TGF-b1, TGF-a, BMP-7, and insulin) was significantly increased in the supernatant of U87EGFRvIII cells compared with U87 cells and decreased dramatically when HM13 was knocked down ( Figure 3B ). ELISA assays further confirmed the increase in Figure 4 The supernatant of U87EGFRvIII when HM13 knockdown regulated the activity of the TGF-b signaling pathway in vitro. expression of the four cytokines in the supernatant of U87EGFRvIII cells and subsequent reduction when treated with Lenti-siHM13 (data not shown). Furthermore, the expression of other cytokines substantially increased ( Figure 3C ) in the supernatant of U87EGFRvIII cells compared with U87 cells and decreased sharply ( Figure 3D ) after treatment with LentisiHM13, indicating that there are distinct differences between U87EGFRvIII and U87 secretion profiles and that SPP plays an important role in regulating EGFRvIII cancer cell secretion profiles.
HM13 Knockdown Regulates TGF-b1 Secretion in EGFRvIII Cancer Cells and Affects Surrounding Cell Biological Behaviors through the TGF-b Pathway In Vitro
We have demonstrated that HM13 knockdown affects cytokines in EGFRvIII secretion profiles, which is often associated with tumor biological behaviors; thus, we performed a reporter assay to evaluate the TGF-b pathway activity when cells were cultured with the supernatants of differently treated U87-EGFRvIII cells Figure 4A ). We collected the supernatants from U87-EGFRvIII cancer cells treated with Lenti-NC or Lenti-siHM13, added the supernatant samples to U87 cells and then extracted the nuclei, cytoplasm, and total proteins of the cells for Western blot ( Figure 4B ). We also performed immunofluorescent staining on these cells ( Figure 4C ). Both results indicated that when cultured with supernatant derived from U87EGFRvIII cancer cells infected by Lenti-siHM13, cells showed a clear decrease in nuclear localization of p-smad2 and p-smad3, which are essential for TGF-b pathway activation.
To further validate these findings, we designed a pre-TGF-b1 lentivirus with red fluorescent protein for tracking the transportation process of TGF-b1 ( Figure 5C ). We found that EGFRvIII cells, when treated with Lenti-siHM13, exhibited an obvious accumulation of pre-TGF-b1 and a clear decrease in expression of polymerase I and transcript release factor (PTRF) (Figure 5D ), suggesting that SPP knockdown greatly influenced the maturation of secreted proteins in EGFRvIII cancer cells and subsequently affected the biological behaviors of surrounding cells.
To determine whether our findings are relevant to biological behaviors, we collected the supernatant of U87EGFRvIII cells treated with Lenti-siHM13, TGF-b1 neutralizing antibody, and Lenti-NC and then cultured different glioma cell lines with these supernatant samples. Transwell ( Figure 5A,B) results showed that cells cultured using the supernatant of U87EGFRvIII treated with Lenti-siHM13 had a significantly reduced invasiveness ability.
HM13 Knockdown in U87EGFRvIII Cancer Cells Improved Mice Survival and Inhibited Orthotopic Tumor Growth
To further confirm the stimulative role of HM13 and explore the therapeutic potential of depleting HM13, we established orthotopic mouse models using U87EGFRvIII cancer cells infected with Lenti-siHM13 or Lenti-NC. Engraftment of the treated U87EGFR-vIII cancer cells into the mice resulted in completely different survival times ( Figure 6A ) and tumor volumes ( Figure 6C ). These results indicated that groups treated with Lenti-siHM13 had a longer survival time and smaller tumor volume. Furthermore, no metastatic foci were observed compared with Lenti-NC groups.
To further verify the effect of HM13 knockdown on EGFRvIII secretion profiles, we collected mice blood from the two groups and detected the concentration of cytokines (TGF-b1 and TGF-a) using ELISA. Consistent with the findings in vitro, the two cytokines exhibited a statistically significant reduction in expression compared with the control animals ( Figure 6B ). Furthermore, confocal microscopy showed the decreased expression of TGF-b1 and p-smad2 in animal tissue sections when treated with Lenti-siHM13 ( Figure 6D ). Altogether, these mouse experiments demonstrate that HM13 knockdown inhibits tumor progression in vivo.
Discussion
Approximately 3-5% of all membrane proteins are tailanchored proteins [17] , and signal peptide peptidase (SPP), which catalyzes the intramembrane cleavage of signal sequence stubs left in the ER membrane after signal peptidase (SP)-mediated processing of the precursor protein, plays an important role in the maturation of these proteins [18, 19] . Previously, we had identified that specifically inhibiting the activity of signal peptidase could suppress tumor growth in an EGFRvIII/wt heterogenic model by abrogating the secretion of progrowth factors from EGFRvIII cells [20] . Here, we analyzed the relative gene expression and survival period from TCGA, CGGA, REMBRANDT, and GSE16011 databases, knocked down HM13 gene, and established an intracranial model in mice to investigate the effect of HM13 on EGFRvIII secretion profiles and tumor progression (Figure 7) . HM13 was required for dislocation of TGF-b1 from the endoplasmic reticulum, which is consistent with the findings of Hidde L. Ploegh et al. [8] . Therefore, our results suggest that signal peptide peptidase (HM13) may be a potential diagnostic biomarker and therapeutic target for glioblastoma.
It has been shown that secretory vesicles can transfer some of their contents to other cell types [21] [22] [23] , act to promote tumor growth and invasiveness, and suppress the immune response [24] [25] [26] [27] . SPP is implicated in the clearance of signal peptides of secreted proteins as well as misfolded membrane proteins [28, 29] . In our experiments, we tracked the TGF-b1 expression at different time points and under different treatment conditions. The results showed that the expression of TGF-b1 varied with time and knockdown treatment. Interestingly, the expression of PTRF was also changed, and presumably, this phenomenon is related to RNA interference. Furthermore, when HM13 was knocked down, the activity of the TGF-b signaling pathway was obviously affected, as was the biological behavior of tumor cells, especially concerning cell invasive behavior. Therefore, we considered that signal peptide peptidase could facilitate the growth of surrounding tumor cells by affecting the expression of secretory proteins and promoting the progression of the entire tumor. 
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